Publications by authors named "E Cutler"

Introduction: Among older adults with cancer receiving chemotherapy, frailty indices predict OS and toxicity. Given the increased use of immunotherapy and targeted therapy for advanced non-small cell lung cancer (aNSCLC), we evaluated frailty and Karnofsky Performance Status (KPS) among older adults with aNSCLC receiving chemotherapy, immunotherapy, and/or targeted therapy.

Methods: Patients aged ≥ 65 with aNSCLC starting systemic therapy with non-curative intent underwent geriatric assessments over 6 months.

View Article and Find Full Text PDF

Background: Dual HIV/syphilis testing may be an acceptable intervention to identify men with sexually transmitted infections (STIs) and at risk of HIV acquisition.

Objectives: We sought to determine the acceptability, and performance of dual HIV/syphilis testing among men attending voluntary medical male circumcision (VMMC) services at six public sector facilities in Gauteng.

Method: This was a cross-sectional study at VMMC facilities.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer-associated fibroblasts (CAFs) in B-cell precursor acute lymphoblastic leukemia (B-ALL) originate from bone marrow-derived mesenchymal stromal cells (MSCs) and are influenced by reactive oxygen species from chemotherapy.
  • The study shows that exposure of MSCs to B-ALL cells or their secretions initiates the CAF formation, marked by a strong interferon pathway response.
  • A key finding is that leukemia cell-derived mitochondrial double-stranded RNA (dsRNA) stimulates MSCs to transition into CAFs, and disrupting dsRNA can block this process, revealing a new way cancer cells interact with their environment.
View Article and Find Full Text PDF

Background: Point-of-care (POC) rapid recency testing can be used as a cost-effective tool to identify recently infected individuals (i.e. infected within the last 12 months) in near-real time, support epidemic control and identify hotspots for transmission as part of recent infection surveillance.

View Article and Find Full Text PDF

Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual patient level, drug resistance results assist in ensuring unnecessary treatment switches are avoided and subsequent regimens are tailored on a case-by-case basis, should resistance be detected. Although there is a disparity in access to HIVDR testing in high-income countries compared to low- and middle-income countries (LMICS), more LMICs have now included HIVDR testing for individual patient management in some groups of patients.

View Article and Find Full Text PDF